New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
10:20 EDTBSXBoston Scientific gets CE Mark approval for INGEVITY MRI pacing leads
Boston Scientific Corporation announces CE Mark approval and European market launch of the INGEVITY family of magnetic resonance imaging compatible pacing leads.
News For BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
16:08 EDTBSXBoston Scientific agrees to acquire Xlumena
Subscribe for More Information
March 31, 2015
14:55 EDTBSXBoston Scientific volatility at historic lows as shares near eight-year high
Subscribe for More Information
March 24, 2015
16:06 EDTBSXBoston Scientific announces first commercial procedures with Watchman Device
This week, three patients in the U.S. received the first implants of the Boston Scientific Watchman Left Atrial Appendage Closure, or LAAC, Device. The WATCHMAN Device offers a novel stroke risk reduction option for high-risk patients with non-valvular atrial fibrillation, or AF, who are seeking an alternative to long-term warfarin therapy. The Watchman Device received FDA approval on Friday, March 13. The first Watchman Device procedures in the U.S. were performed by Shephal K. Doshi, M.D., director of Cardiac Electrophysiology and Pacing at Saint John's Health Center in Santa Monica, CA, and Saibal Kar, M.D., director of the Cardiovascular Intervention Center Research at Cedars-Sinai Hospital in Los Angeles, CA.
March 23, 2015
16:19 EDTBSXBoston Scientific leads funding round for InterVene
Subscribe for More Information
March 20, 2015
10:00 EDTBSXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:32 EDTBSXBoston Scientific has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Mike Mahoney on March 27 at 11 am.
06:44 EDTBSXBoston Scientific initiated with an Outperform at Raymond James
Subscribe for More Information
March 18, 2015
05:39 EDTBSXSt. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use